Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus
Regeneron Pharmaceuticals reported positive Phase 1/2 data for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, with all patients achieving hematologic responses and organ improvement in those with organ involvement. This news provides a new late-stage asset for investors to monitor within Regeneron's pipeline, especially as detailed results are anticipated at ASCO 2026. The stock is currently trading below analyst targets and an internal fair value estimate, despite the promising clinical data.
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Crescent Biopharma (CBIO) has not yet received any FDA approvals for its therapy CR-001, which is being investigated for the treatment of advanced solid tumors. The company recently announced a poster presentation for its ASCEND study of CR-001 at the 2026 ASCO Annual Meeting and previously reported dosing the first patient in its global Phase 1/2 clinical trial for the drug. Crescent Biopharma anticipates multiple data readouts for CR-001 starting in Q1 2027.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
Pomerantz LLP is investigating Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Regeneron's May 15, 2026 announcement that a Phase 3 trial for fianlimab in combination with cemiplimab for melanoma treatment did not achieve statistical significance for its primary endpoint, leading to a significant drop in Regeneron's stock price on May 16, 2026.
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
The first quarter of this year saw an uptick in biopharma sales, with eight of the top-25 companies achieving double-digit year-over-year growth, compared to six in each quarter of 2025. Eli Lilly led the growth with a 56% increase, extending its reign as the top performer for six consecutive quarters. Other significant contributors to this growth included Regeneron, AstraZeneca, AbbVie, Sandoz, Johnson & Johnson, Astellas, and Daiichi Sankyo, while Novo Nordisk experienced the largest sales decline for the second consecutive quarter.
Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS
This article provides key financial data for Regeneron Pharmaceuticals, Inc. (BVL:REGNUS), focusing on its cash flow activities. It reports that the free cash flow for Q1 2026 was 2.97 billion PEN, while for 2025, it stood at 13.73 billion PEN, with operating cash flow at 16.76 billion PEN. The data covers operating, investing, and financing activities over several years, displayed in tabular and graphical formats.
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Regeneron Pharmaceuticals Inc. (REGN) stock fell 1.10% on Thursday, closing at $642.59, despite an overall positive trading session for the broader market. This drop ended a two-day winning streak for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
Jim Cramer discussed Regeneron Pharmaceuticals (NASDAQ: REGN) after the company experienced a significant drop due to an unsuccessful metastatic melanoma cancer trial. He noted that most analysts had relied on this drug for their stock recommendations, and despite his previous positive outlook, Cramer now anticipates more downgrades for REGN. Cramer suggests investors consider AI stocks with greater upside potential instead of "damaged" drug stocks.
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on developing conditionally activated biologics for cancer treatment, will provide a live webcast of its presentations and be available for one-on-one meetings with investors at both events.
The Escalator: Amgen, CG Life, Cosette Pharmaceuticals and more
This article, "The Escalator," details recent personnel changes and key events across the pharma, biotech, and medical marketing industries. It highlights new hires at companies like Amgen, CG Life, and Cosette Pharmaceuticals, executive elevations within regulatory bodies, and significant board appointments. The piece also covers notable departures, miscellaneous industry news including FDA analyses, political actions, and philanthropic partnerships.
Booking Stock Delivers Strong Cash Yield – Upside Ahead?
Booking Holdings (BKNG) stock is presented as a strong potential investment due to its high cash yield, robust fundamentals, and discounted valuation. The article highlights BKNG's 7.3% free cash flow yield and 34.3% operating margin, comparing them favorably to S&P medians. It also suggests that a portfolio approach to high-yield stocks can offer better returns and mitigate single-stock risks compared to individual investments.
Regeneron backed Parabilis seeks U.S. IPO (PBLS:Pending)
Parabilis Medicines, a clinical-stage biopharma company, has filed with the SEC for a U.S. IPO. This move follows a significant research partnership with Regeneron Pharmaceuticals, valued at up to $2.3 billion. The IPO aims to secure further funding for the company's growth.
ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospects
Sanofi and Regeneron presented mixed Phase III trial results for itepekimab in COPD at ATS 2026, with AERIFY-1 showing significant exacerbation reductions but AERIFY-2 failing to replicate these findings. This inconsistency poses a significant hurdle for FDA approval, especially compared to AstraZeneca's tozorakimab, which demonstrated consistent efficacy across two trials. Despite this setback, Sanofi and Regeneron maintain a strong presence in the respiratory market with Dupixent and continue to explore itepekimab for other indications like chronic rhinosinusitis with nasal polyps.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Regeneron Pharmaceuticals Inc. (REGN) saw its stock rise by 3.24% on Wednesday, closing at $649.76. This strong performance occurred on a positive day for the broader market, with the S&P 500 Index and Dow Jones Industrial Average also posting gains. This marks the second consecutive day of increases for Regeneron's stock.
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
Levi & Korsinsky, LLP is investigating Regeneron Pharmaceuticals, Inc. (REGN) for potential securities fraud following a sharp drop in shares. This comes after the failure of a Phase 3 trial for fianlimab plus Libtayo in metastatic melanoma, a drug combination Regeneron executives had recently described as a "potential blockbuster." The investigation focuses on whether Regeneron's statements about the trial's progress adequately reflected available information.
Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
Tredje AP fonden has initiated a new position in Regeneron Pharmaceuticals, purchasing 16,330 shares valued at approximately $12.6 million. Regeneron recently reported strong quarterly results, with EPS of $9.47 on revenues of $3.61 billion, an increase of 19% year-over-year. The company also declared a quarterly dividend of $0.94 per share, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $792.65, despite recent stock weakness due to a late-stage melanoma trial failure and subsequent analyst price target cuts.
Sanofi S.A. stock (FR0000120578): diabetes and immunology pipeline in focus after recent updates
Sanofi S.A. has recently shared updates on its diabetes and immunology pipeline, including its blockbuster drug Dupixent and new once-weekly insulin candidates, as it shifts its strategic focus towards higher-growth specialty care drugs and vaccines. The company's performance will depend on its R&D strategy, competitive landscape, and regulatory developments, particularly in the US market, which is a significant revenue driver. Sanofi offers US investors exposure to a diversified pharmaceutical portfolio via its American Depositary Receipts.
Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom
Nektar Therapeutics has appointed Linda Rubinstein as its new Chief Financial Officer, succeeding Sandra Gardiner. This leadership change comes as Nektar, a loss-making biopharmaceutical company, faces significant funding and potential dilution questions, particularly after a recent $150 million equity offering. Rubinstein's extensive background in capital-raising and M&A in development-stage life sciences companies is expected to be crucial in managing the company's financial strategy, clinical programs, and partnerships, as investors closely monitor her approach to cash runway and future equity issuance.
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Harvest Portfolios Group Inc. reduced its stake in Regeneron Pharmaceuticals (REGN) by 24% in Q4, now holding 81,748 shares valued at approximately $63.1 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" consensus for REGN with an average price target of $792.65. Regeneron Pharmaceuticals recently beat earnings expectations with $9.47 EPS and $3.61 billion in revenue, and declared a quarterly dividend of $0.94 per share.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
Fideuram Intesa Sanpaolo Private Banking S.P.A. has initiated a new position in Regeneron Pharmaceuticals, Inc. by purchasing 23,047 shares valued at approximately $17.8 million during the fourth quarter. This move comes despite recent pressure on Regeneron due to a failed late-stage melanoma trial, though the company did report strong Q1 results with revenue up 19% year-over-year and beating EPS estimates. Analysts maintain a "Moderate Buy" rating for REGN with an average price target of $792.65, indicating potential upside.
Is It Time To Reconsider Vertex Pharmaceuticals (VRTX) After The Recent Share Price Pullback
Vertex Pharmaceuticals (VRTX) has experienced a recent share price pullback, leading to questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 46.1%, with an estimated intrinsic value of $805.27 per share against a current price of $434.31. However, its P/E ratio is above the biotech industry average, hinting that the current valuation is "about right" when considering its growth profile and risks.
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Alnylam Pharmaceuticals recently reported positive HELIOS-B Phase 3 data for vutrisiran, demonstrating durable transthyretin knockdown and consistent clinical benefits for high-risk ATTR-CM patients, alongside launching the DemonsTTRate real-world study. This strengthens the clinical case for vutrisiran within Alnylam's TTR franchise, which continues to drive strong financials, with Q1 2026 revenues of US$1.17 billion and a reiterated 2026 guidance of US$4.4-4.7 billion from TTR products. While these developments bolster the investment narrative around the TTR portfolio's durability, investors should remain mindful of potential pricing pressures on AMVUTTRA.
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy
CFRA has lowered its rating on shares of Regeneron Pharmaceuticals, Inc. from "Buy" to "Hold." This downgrade reflects a revised outlook on the company's stock by CFRA analysts.
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations – Company Announcement - FT.com
SueWallSt has initiated an investigation into Regeneron Pharmaceuticals (NASDAQ: REGN) for potential securities law violations after the company's stock dropped over 10% following the announcement that its Phase 3 melanoma trial of Fianlimab + Libtayo failed to meet its primary endpoint. This downturn occurred despite earlier optimistic statements from Regeneron executives regarding the trial's prospects. Investors who suffered losses are encouraged to contact SueWallSt to discuss their legal rights.
Upbound Group executive vice president and general counsel Bryan Pechersky to resign
Upbound Group announced that Bryan Pechersky, Executive Vice President, General Counsel, and Corporate Secretary, will resign effective June 5, 2026. This decision was not due to any disagreements with the company's operations or policies. The company, based in Plano, Texas, maintains a strong dividend yield and is considered undervalued by InvestingPro, despite recently reporting mixed Q1 2026 earnings with an EPS beat but a revenue miss.
North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN
The North Dakota State Investment Board recently acquired 3,579 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) during the fourth quarter, valued at approximately $2.76 million. This new position comes despite a recent 9.8% drop in Regeneron's stock following a failed Phase 3 melanoma trial and subsequent analyst price-target cuts. Nevertheless, the biopharmaceutical company reported strong Q1 earnings with EPS of $9.47 and revenue of $3.61 billion, exceeding expectations, and declared a $0.94 quarterly dividend.
Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off
Regeneron Pharmaceuticals Inc has announced a strategic collaboration with Parabilis Medicines to develop Helicon peptide-based antibody conjugates, aiming to expand its drug discovery pipeline and target "undruggable" diseases. This announcement comes as Regeneron's stock (REGN) has experienced significant volatility and a recent sell-off, partly due to clinical setbacks like a failed melanoma study. Despite a track record of beating earnings estimates, the company faces pressure on its older franchises, making the Parabilis deal a key move for future growth and diversification.
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Regeneron Pharmaceuticals has forged a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates utilizing Parabilis's Helicon peptide platform, focusing on antibody-Helicon conjugates (AHCs). Parabilis stands to receive $125 million upfront, including a $50 million payment and a $75 million investment, with potential for up to $2.2 billion in additional milestone payments and tiered royalties. This partnership aims to tackle previously undruggable targets and introduce a new class of therapies by combining Helicons with Regeneron's VelocImmune-derived antibodies for precise cellular delivery.
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook
Regeneron Pharmaceuticals' Phase 3 trial for fianlimab plus cemiplimab in advanced melanoma failed to meet its primary endpoint, leading to a recent stock price decline. Concurrently, Regeneron announced a new research collaboration with Parabilis Medicines, focusing on Helicon peptide technology for targeting intracellular proteins. These developments will likely cause investors to re-evaluate Regeneron's oncology pipeline, shifting focus towards the potential of the new collaboration while acknowledging the setback in its late-stage melanoma program.
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook
Regeneron Pharmaceuticals (REGN) recently faced a setback with its Phase 3 melanoma trial failing to meet its primary endpoint, leading to an immediate negative impact on its stock price. However, the company also announced a new research collaboration with Parabilis Medicines focusing on innovative Helicon peptide technology, which introduces a new avenue for its long-term oncology pipeline. This development shifts investor focus from the recent trial failure to the potential of this new partnership and how Regeneron will manage its future R&D efforts.
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were down on Monday, with several major stocks experiencing pre-market declines. UnitedHealth Group fell after Berkshire Hathaway diluted its position, while Regeneron Pharmaceuticals dipped following unsuccessful Phase 3 trials. Other companies like Amtech Systems, Li Auto, and Icahn Enterprises also saw their stock prices decrease.
Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out?
This article compares Incyte (INCY) and Regeneron Pharmaceuticals (REGN), suggesting Incyte as the more attractive investment. Incyte shows superior revenue growth, higher operating margins, and a lower valuation compared to Regeneron. Historical market performance data also indicates that Incyte has delivered better returns and higher monthly win rates.
Regeneron stock sinks after cancer trial miss prompts selloff
Regeneron Pharmaceuticals shares dropped significantly after its late-stage melanoma drug trial, involving a combination of fianlimab and cemiplimab, failed to meet its primary goal of statistical significance for improving progression-free survival. This setback adds pressure amidst weakening Eylea sales, despite the company's efforts to expand its pipeline through a new partnership with Parabilis Medicines. Analysts expressed concern, with some labeling it a "worst-case scenario" for Regeneron's cancer prospects.
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
Levi & Korsinsky, LLP has initiated an investigation into Regeneron Pharmaceuticals (REGN) concerning potential misleading statements made by officers and directors. This follows a significant stock drop after Regeneron's Phase 3 melanoma trial failed to meet its primary endpoint, contradicting earlier optimistic executive statements. The law firm is encouraging investors who suffered losses to come forward to discuss their legal rights.
Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy
CFRA has downgraded its rating on Regeneron Pharmaceuticals, Inc. (REGN) shares from "Buy" to "Hold" while maintaining a 12-month price target of $925.00. This adjustment is based on a conservative view of the company's growth outlook for its key drugs Eylea and Dupixent, increased competition, and potential changes in market share for Eylea.
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Analyst Downgrade
Regeneron Pharmaceuticals (NASDAQ:REGN) saw its shares gap down after Truist Financial lowered its price target, impacting trading negatively. This downgrade followed a clinical setback for its melanoma drug fianlimab and other analysts also reducing price targets, despite the company recently reporting strong quarterly earnings and announcing a dividend. The stock maintains a "Moderate Buy" consensus rating from analysts, with insider selling also noted.
New sinus and asthma drug trial slashes steroid use, sinus surgery by 83%
Upstream Bio (NASDAQ: UPB) announced new Phase 2 VIBRANT trial data for verekitug, demonstrating significant improvements in asthma symptom control and an 83% reduction in the need for rescue systemic steroids or CRSwNP surgery for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. The drug also showed rapid and sustained reductions in type 2 inflammatory biomarkers. The company plans to begin Phase 3 trials in CRSwNP and severe asthma in Q1 2027.
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
Regeneron has entered a collaboration with Parabilis Medicines, committing up to $2.3 billion to develop a new class of therapeutics called antibody-helicon conjugates (AHCs). This partnership aims to combine Regeneron's antibody-drug conjugate (ADC) capabilities with Parabilis' peptide platform to target previously "undruggable" proteins. The news follows a recent Phase 3 clinical trial miss for Regeneron, which has impacted investor confidence.
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines has entered a strategic collaboration with Regeneron Pharmaceuticals to develop Antibody-Helicon™ Conjugates (AHCs) for challenging therapeutic targets. The agreement includes a $50 million upfront payment, a $75 million equity commitment, and potential milestone payments of up to $2.2 billion, plus tiered royalties. This partnership aims to leverage Parabilis's Helicon™ peptide platform with Regeneron's antibody expertise to address previously undruggable intracellular protein targets.
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
Regeneron Pharmaceuticals Inc. experienced premarket stock declines and Wall Street downgrades after its phase 3 trial for fianlimab in advanced melanoma failed to meet statistical significance compared to Merck's Keytruda. Although the drug combination showed numerical improvement in progression-free survival, it did not cross the statistical threshold, leading analysts like Citi and BMO to lower their ratings and price targets for the company. This setback follows earlier disappointing phase 2 data for fianlimab in non-small cell lung cancer, diminishing the drug's future commercial prospects.
Pancreatic cancer RNAi trial moves ahead as Silexion ramps up spending
Silexion Therapeutics (NASDAQ: SLXN) reported its Q1 2026 financial results, highlighting progress on its SIL204 clinical trial for locally advanced pancreatic cancer, including regulatory approvals in Israel and Germany. While the company saw increased R&D spending and a wider net loss, it successfully raised capital post-quarter to meet Nasdaq's minimum shareholders' equity requirement. The Phase 2/3 trial for SIL204 is expected to commence in Q2 2026.
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were down on Monday, with the Nasdaq futures falling around 100 points. Several large-cap stocks experienced significant drops in pre-market trading, including UnitedHealth Group, Regeneron Pharmaceuticals, and Li Auto, primarily due to company-specific news or broader market sentiment. Each company's decline was attributed to factors like Berkshire Hathaway's divestment, unsuccessful clinical trials, or previous day's performance.
6M women get high-risk HPV yearly; new trial tests first potential drug
Daré Bioscience has initiated a Phase 2 clinical study for DARE-HPV, a novel pharmacologic treatment for persistent high-risk HPV infection, which currently has no FDA-approved therapies. This randomized, placebo-controlled trial will evaluate the safety and antiviral activity of DARE-HPV in approximately 100 women, with topline data expected in 2027. The program, backed by a $10 million ARPA-H contract, aims to intervene earlier in the infection process to prevent cervical cancer and address a significant unmet medical need affecting 6 million women annually in the U.S.
Kyverna taps ex-Ironwood CFO to fund CAR T autoimmune push
Kyverna Therapeutics has appointed Greg Martini, formerly of Ironwood Pharmaceuticals, as its new Chief Financial Officer, effective May 18, 2026. Martini will head the company's financial strategy as it progresses its CAR T candidate, miv-cel (KYV-101), towards potential approval for stiff person syndrome and a commercial launch. The appointment comes with an inducement option for Martini to purchase 325,000 shares, vesting over four years.
S&P 500 Futures Fall in Premarket Trading; Victory Capital, Regeneron Pharmaceuticals Lag
S&P 500 futures are down in pre-market trading, with Victory Capital and Regeneron Pharmaceuticals lagging. However, Dominion Energy Inc. and Bio-Rad Laboratories Inc. Cl A showed significant gains before the market opened.
Rare Disease Therapeutics Market 2025-2033 | Market Growth
The Rare Disease Therapeutics Market is projected for significant growth between 2025 and 2033, driven by strategic initiatives from key players, technological advancements, and evolving demand patterns. Valued at US$ 135.88 billion in 2023, it is expected to reach US$ 495.27 billion by 2033 with a CAGR of 13.8%. Recent developments include major acquisitions, expanded clinical programs, and advancements in gene and RNA-based therapies by leading pharmaceutical companies.
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
Regeneron's LAG-3 inhibitor, fianlimab, combined with Libtayo, failed to show superior survival benefits compared to Merck's Keytruda in a Phase 3 study for unresectable or metastatic melanoma. This late-stage miss, following a previous clinical trial failure in COPD, has shaken analyst confidence in Regeneron's R&D execution. The company's shares dropped 10% following the announcement.
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Regeneron Pharmaceuticals shares decreased premarket by over 10% after its late-stage clinical trial for a skin cancer medication failed to meet its primary goal. The trial, comparing Regeneron's two-drug combination of Fianlimab and cemiplimab against a Bristol Myers Squibb medication, aimed to slow cancer progression in newly diagnosed melanoma patients but was unsuccessful. This setback follows a year-to-date decline of 9.5% for Regeneron's stock.
Regeneron pursues up to $2.2B in Helicon milestones on 'undruggable' diseases
Regeneron has announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs) for historically "undruggable" intracellular targets. The agreement includes an upfront payment of $50 million, a $75 million equity commitment, and potential milestone payments up to approximately $2.2 billion for Parabilis. This partnership aims to combine Regeneron's antibody capabilities with Parabilis's Helicon™ peptide platform to create a new class of therapeutics capable of targeting challenging proteins across multiple therapeutic areas.
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines has announced a strategic collaboration with Regeneron Pharmaceuticals to discover and develop novel Antibody-Helicon™ Conjugates (AHCs) and stand-alone Helicon therapies across multiple therapeutic areas, targeting challenging intracellular proteins. The agreement includes a $50 million upfront payment and a $75 million equity commitment from Regeneron, with potential milestone payments up to $2.2 billion and tiered royalties. This partnership aims to combine Parabilis's Helicon peptide platform with Regeneron's antibody expertise to address previously "undruggable" targets.
Why Is Regeneron Stock Sinking Monday?
Regeneron Pharmaceuticals' stock is plummeting due to its Phase 3 melanoma trial for fianlimab missing its primary endpoint of improved progression-free survival compared to Merck's Keytruda. Although a high-dose combination showed numerically higher survival, it failed to meet statistical significance. Despite this setback, Regeneron recently partnered with Telix Pharmaceuticals to expand its oncology efforts in radiopharmaceutical therapies.
